Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors

• Main Authors: Praveen Dilip Chatani, Sunita Kishore Agarwal, Samira Mercedes Sadowski
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-01-01
• Series: Frontiers in Endocrinology
• Subjects: molecular signatures; signaling pathway; tumorigenesis; clinical trial; neuroendocrine carcinoma; pancreatic neuroendocrine tumor
• Online Access: https://www.frontiersin.org/articles/10.3389/fendo.2020.575620/full

Pancreatic neuroendocrine tumors (PNETs) are classified based on their histologic differentiation and proliferative indices, which have been used extensively to determine prognosis. Advances in next-generation sequencing and other high-throughput techniques have allowed researchers to objectively explore tumor specimens and learn about the genetic alterations associated with malignant transformation in PNETs. As a result, targeted, pathway-specific therapies have been emerging for the treatment of unresectable and metastatic disease. As we continue to trial various pharmaceutical products, evidence from studies using multi-omics approaches indicates that clinical aggressiveness stratifies along other genotypic and phenotypic demarcations, as well. In this review, we explore the clinically relevant and potentially targetable molecular signatures of PNETs, their associated trials, and the overall differences in reported prognoses and responses to existing therapies.